Adagene says China NMPA clears IND for ADG138 HER2xCD3 bispecific T-cell engager
ADAG•China NMPA clears IND for ADG138
- China’s NMPA cleared Adagene’s IND for ADG138, a double-masked HER2xCD3 bispecific T-cell engager for advanced solid tumors.
- First-in-human Phase 1 trial in China is scheduled to start in Q4 2026.
